Apricus Biosciences Inc

Find Ratings Reports
APRI : NASDAQ : Health Care
$0.95 | %
Today's Range: 0.91 - 0.99
Avg. Daily Volume: 439100.0
05/26/17 - 4:00 PM ET

Financial Analysis


APRICUS BIOSCIENCES INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. APRICUS BIOSCIENCES INC has very weak liquidity. Currently, the Quick Ratio is 0.23 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity decreased from the same period a year ago, despite already having very weak liquidity to begin with. This would indicate deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has increased by 24.41% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)0.362.63
EBITDA ($mil)-2.4-3.34
EBIT ($mil)-2.47-3.41
Net Income ($mil)-0.3-2.33


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)2.094.17
Total Assets ($mil)4.77.86
Total Debt ($mil)6.659.48
Equity ($mil)-7.52-9.94


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin99.44-126.85
EBITDA Margin-673.03-126.85
Operating Margin-693.26-129.75
Sales Turnover1.230.62
Return on Assets-158.14-242.17
Return on Equity0.00.0
Debt Q4 FY16 Q4 FY15
Current Ratio0.320.4
Debt/Capital-7.68-20.2
Interest Expense0.230.3
Interest Coverage-10.55-11.33


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)7.735.04
Div / share0.00.0
EPS-0.04-0.5
Book value / share-0.97-1.97
Institutional Own % n/a n/a
Avg Daily Volume477152.01348160.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
APRI NM Peers 87.33   APRI NM Peers 19.75

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

APRI's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

APRI's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
APRI 16.83 Peers 15.90   APRI NA Peers 0.73

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

APRI's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
APRI NM Peers 13.78   APRI 56.85 Peers -3.58

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

APRI's P/B is negative making this valuation measure meaningless.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

APRI is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
APRI 1.36 Peers 14.05   APRI 19.09 Peers 4.04

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

APRI is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

APRI has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades